Service de Biochimie et Génétique Moléculaire, CHU Limoges, France.
Université de Limoges, MMNP, Limoges, France.
Ann Clin Transl Neurol. 2021 Feb;8(2):471-476. doi: 10.1002/acn3.51175. Epub 2021 Jan 6.
We describe the clinical, electrodiagnostic, and genetic findings of three homozygous FIG4-c.122T>C patients suffering from Charcot-Marie-Tooth disease type 4J (AR-CMT-FIG4). This syndrome usually involves compound heterozygosity associating FIG4-c.122T>C, a hypomorphic allele coding an unstable FIG4-p.Ile41Thr protein, and a null allele. While the compound heterozygous patients presenting with early onset usually show rapid progression, the homozygous patients described here show the signs of relative clinical stability. As FIG4 activity is known to be dose dependent, these patients' observations could suggest that the therapeutic perspective of increasing levels of the protein to improve the phenotype of AR-CMT-FIG4-patients might be efficient.
我们描述了三位同种型 FIG4-c.122T>C 纯合子患者的临床、电诊断和遗传发现,他们患有 Charcot-Marie-Tooth 病 4J 型(AR-CMT-FIG4)。该综合征通常涉及 FIG4-c.122T>C 的复合杂合性,该等位基因编码不稳定的 FIG4-p.Ile41Thr 蛋白,为功能缺失性等位基因。尽管具有早期发病表现的复合杂合子患者通常具有快速进展,但这里描述的纯合子患者表现出相对临床稳定的迹象。由于已知 FIG4 活性具有剂量依赖性,这些患者的观察结果表明,增加蛋白水平以改善 AR-CMT-FIG4 患者表型的治疗前景可能是有效的。